Increased Burden of Familial-associated Early-onset Cancer Risk among Latino

Americans Compared to non-Latino Whites.

Qianxi Feng, MPH [1], Eric Nickels, MD [1,2], Ivo S. Muskens, MD [1], Adam J. de Smith, PhD [1], W.

James Gauderman, PhD [1], Amy C. Yee, MPH [1], Charite Ricker, MS, CGC [3], Thomas Mack, MD

[1], Andrew D. Leavitt, MD [4], Lucy A. Godley, MD, PhD [5], Joseph L. Wiemels, PhD [1]

Affiliations of authors:

[1] Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA

[2] Children's Hospital Los Angeles, Los Angeles, CA

[3] Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA

[4] Departments of Medicine and Laboratory Medicine, University of California, San Francisco,

San Francisco, CA

[5] Departments of Medicine and Human Genetics, The University of Chicago, Chicago, IL
15

Correspondence to:

Joseph L. Wiemels

Professor, Department of Preventive Medicine

Center for Genetic Epidemiology

1450 Biggy Street, NRT-1506

Los Angeles, CA 90089

(323) 442-7865

wiemels@usc.edu

Abstract

The role of race/ethnicity in genetic predisposition of early-onset cancers can be estimated by

comparing family-based cancer concordance rates among ethnic groups. We used linked

California health registries to evaluate the relative cancer risks for first degree relatives of

patients diagnosed between ages 0-26, and the relative risks of developing distinct second

malignancies (SPMs). From 1989-2015, we identified 29,631 cancer patients and 62,863

healthy family members. Given probands with cancer, there were increased relative risks of any

cancer for siblings and mothers [standardized incidence ratio (SIR)=3.32;95% confidence

interval (CI):2.54-4.35;$P<0.001$)]and of SPMs (SIR=7.12;95%CI:5.46-9.28;$P<0.001$). Higher

relative risk of any cancer in siblings and mothers (P=0.001) was observed for Latinos

(SIR=3.36;95%CI:2.24-5.05) compared to non-Latino White subjects (SIR=2.60;95%CI:1.66-

4.06). Latinos had higher relative risks in first degree relatives and higher SPM risk compared to

non-Latino Whites for most cancers, supporting a need for increased attention to the genetics of

early-onset cancer predisposition in Latinos.

(150 words)

Keywords: Early-onset cancer; Familial risk; Linked cancer registry; Race/ethnicity; Latino

Americans; Hispanic paradox.

Key Messages

• We identified 29 631 cancer patients and their 62 863 healthy family members in

California from 1989 to 2015.

• The risk of early-onset cancer in siblings and mothers was elevated by having a proband

with cancer in the same family.

• The majority of early-onset cancers exhibited higher relative risks in siblings and

mothers and second primary malignancies for Latinos when compared to non-Latino

Whites.

Introduction

Both genetic and environmental factors play a role in the causes of early-onset cancer. Several

well-defined genetic syndromes contribute to early-onset cancer risk, along with a wider array of

common alleles that influence risk marginally and detected at the population level. As an

example of the former, Li-Fraumeni syndrome caused by mutations in the tumor suppressor

gene *TP53*, is associated with an increased risk of a spectrum of cancers diagnosed at early

ages[1]. An example of low penetrance common genetic variations associated with cancer risk

include *IKZF1* and *ARID5B* genes in pediatric acute lymphoblastic leukemia (ALL)[2]. Both of

these classes of variants may vary in frequency by race/ethnic group and cluster by families[3-5],

where familial germline deletion of *ETV6* was reported for ALL[6]. Examination of cancer

predisposition requires investigation in ethnic strata particularly where cancer incidence rates

are known to differ as it does for many pediatric cancer types, such as leukemia[7] and brain

cancer[8].

In addition to primary cancers, incidence patterns of second independent malignancies may

also provide a perspective of underlying genetic predisposition. Among childhood cancer

survivors, more second primary malignancy cases are observed among non-Latino Whites

(NLW) than Latino subjects[9]. This is also reflected in adult cancers, where Latino breast cancer

survivors had lower risk of second cancers than NLW and NL Black women[10].

Germline pathogenic/likely pathogenic variants in cancer predisposition genes are found in

approximately 10% of pediatric cancer patients[1,11-13], and may be inherited or arise *de novo*.

Highly penetrant inherited variants will contribute to clustering of cancer cases within the family.

Shared environments within the family unit may also be considered alongside genetic risk as

potential causes for family-based cancer concordance.

Familial concordance of a wide variety of cancers has been assessed using the Swedish

Family-Cancer Database, leading to a deep understanding of familial relative risks[14-16]. The

Victorian Paediatric Cancer Family Study in Australia also explored the cancer risks for relatives

of children with cancer in a small population[17]. In the US, the Utah Population database may be

the best-known population for studying familial risk[18-22]. Importantly, these studies largely

comprise families of European ancestry, and therefore have not examined potential ethnic-

specific familial risks. Here, we utilized linked population registries with over 64,000 individuals

to quantify the familial risks (siblings and mothers) and the risks of early-onset second primary

malignancies in the highly diverse and large population of California.

93
94

Methods

Source of Data

We used linked population-based registries in California to evaluate the relative risks of early-onset cancers (0-26 years age of onset) for siblings and mothers of children, adolescents, and young adults (AYA) aged 0-26 diagnosed with cancer, as well as the relative risks of early-onset second primary malignancies (SPMs) among the proband patients. The dataset was created by linking information from the California Cancer Registry (CCR) and California Birth Statistical Master File, allowing the capture of siblings and parents of cancer probands, along with their cancer incidence. The linked dataset comprehensively encompassed all cancer cases 0-26 years old, as well as their sibling and mother cancers, diagnosed from 1989 to 2015 in California. Our upper age limit of 26 was set based on the available age range covered by this relatively young cohort. Overall, the dataset included a total of 121 571 individuals. The information on healthy siblings and mothers was available during the whole study period, whereas the information on fathers was not available until 2004 in the birth files and therefore is not included in the current analysis.

For the analysis of cancer familial risks, we included all primary incident cancer cases diagnosed from 1989 to 2015 among patients aged 0-26 years, with patient age-at-diagnosis limited by the study time period for which California maintained a statewide SEER gold-standard cancer registry. In addition, we performed a subgroup analysis on pediatric cancers including patients aged 0-15 years diagnosed within the same study period. For the analysis of secondary cancer risks, we included all SPMs diagnosed over the same years and patient age ranges. Although the CCR only records primary malignancies, some misclassification of relapsed or recurrent disease is possible. A physician (E.N.) reviewed diagnosis codes of all the cases diagnosed after the first primary case to prevent the misclassification of relapsed first primary malignancies (FPMs) as SPMs. For both analyses, we classified the cancers into twelve-broad

groups and subgroups as defined by the International Classification of Childhood Cancer, Third

edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html). The abbreviations

for cancer types are included in **Table 1**. We also grouped the cancers into hematologic or solid

categories in the analyses. Hematologic cancers were defined as leukemias and lymphomas.

Solid cancers were defined as CNS tumors, neuroblastomas, retinoblastomas, renal tumors,

hepatic tumors, bone tumors, sarcomas, germ cell tumors, epithelial neoplasms and other and

unspecified malignant neoplasms.

Statistical Analysis

We quantified the relative risks for siblings and mothers, and the relative risks of SPMs by

calculating the standardized incident ratios (SIRs) of a given cancer or of SPMs among the

healthy siblings, and the SIRs of a given cancer among healthy mothers of probands using a

previous published method[14]. We defined a proband as a pediatric or AYA patient with a given

cancer. Only one child/AYA in each family can be a proband, so that in families with two or more

cases, the proband is defined as the patient with the earliest date of diagnosis. Given a proband

with cancer, we calculated the SIRs for a sibling or a mother in the same family for all types of

cancers. Separately, we calculated the SIRs for a sibling for the same type of cancer as the

proband. We also stratified the analyses by self-identified race/ethnicity of the mother in each

family. The SIRs in siblings, mothers or of SPMs can be denoted as:

$$140 \qquad SIR = \frac{O}{E} = \frac{\sum_{i=1}^{N} \sum_{j=1}^{n_i} D_{ij}}{\sum_{i=1}^{N} \sum_{j=1}^{n_i} \sum_{k=1}^{Kmax} \lambda_k t_{ijk}}$$

Where N is the number of families, n_i is the number of non-proband individuals of interest

(siblings/SPMs/mothers) in family i, and Kmax is the total number of age intervals. The data for

each individual includes a disease indicator (D_{ij}) and the number of years "at risk" during the kth

age interval (t_{ijk}). A given individual is defined to be at risk beginning at their age when the

proband in their family is diagnosed and ending either when they become affected themselves

or they are censored due to end of study follow-up. For siblings and mothers, age was stratified

into seven groups as 0, 0-4, 5-9, 10-14, 15-19, 20-24 and 25-29 years. For the calculation of

SIRs within a given race group, λ_k is the race-, sex- and age-specific incidence rate of a given

cancer. We compared the SIRs across race/ethnic groups with approximate Chi-squared tests.

The approximate chi-square method compares the probability of occurrence of events in one

group to another, based on a binomial distribution. This comparison is not related to the 95%

confidence intervals for the SIRs which are based on a Poisson distribution and may overlap

between two groups that are significantly different by approximate chi-square comparison. We

designated that all events occurred right at the middle point of each calendar year. We also

stratified the analysis by 5-year age groups. The 95% confidence intervals (CIs) and p-values

were calculated assuming a Poisson distribution. Statistical analyses were performed using R

software (v 3.6.0). Any two-sided p-value less than 0.05 was considered statistically significant.

A supplement is included with this manuscript with more information on the statistical tests and

computational codes used. Please access this supplement "Statistics and coding supplement:

Familial_risk_CCR_eLife" for more information.

161
Results

Demographics of the study population

From 1989 to 2015, we identified a total of 29 249 pediatric and AYA patients with a primary

malignancy, comprising 29 072 probands, 112 affected siblings (from 110 families) and 65

affected mothers. All siblings were diagnosed after the proband's diagnosis as defined, and 56

(86.15%) of the 65 mothers were diagnosed after the proband's diagnosis. We also identified

387 SPMs among all pediatric and AYA probands (**Table 2**).

Familial relative risks of early-onset cancers

Overall, we found a 3.32-fold (95%CI:2.54-4.35) increased relative risk of any cancer among

siblings and mothers who have a proband with cancer in the same family. Briefly, we found a

2.97-fold (95%CI:1.96-4.50) increased relative risk of any cancer given a proband with

hematologic cancers and a 4.54-fold (95%CI:3.19-6.45) increased relative risk of any cancer

given a proband with solid cancers. When stratified by cancer types, with the exception of

neuroblastomas, hepatic tumors, bone tumors, and malignant neoplasms, proband cancers

siblings and mothers were found to have increased SIRs for any cancer (**Figure 1A**).

For the relative risk of specific cancer types, we found a 2.68-fold (95%CI:1.35-5.32) increased

risk of hematologic cancers among siblings and mothers of a proband with hematologic cancer,

and a 6.78-fold (95%CI:4.18-10.98) increased relative risk of solid cancers among siblings and

mothers of a proband with solid cancer. Furthermore, CNS tumors and epithelial neoplasms

exhibited statistically significantly increased relative risk for the same type of cancer as the

proband [CNS, SIR=6.19; 95%CI:1.42-26.93; epithelial neoplasms, SIR=40.68; 95%CI: 3.17-

521.78] (**Supplementary Table 1**). We also observed increased relative risks for sarcomas

(SIR=7.36;95%CI:1.12-48.23) and epithelial neoplasms (SIR=5.37;95%CI:1.52-18.92) given a

proband with leukemia, for epithelial neoplasms given a proband with CNS tumors

(SIR=6.37;95%CI:1.33-30.41), and for leukemias given a proband with sarcomas

(SIR=7.01;95%CI:1.12-43.92) (**Figure 2 & Supplementary Table 1**).

When stratified by more finely defined cancer subtypes, increased relative risks of any cancer

for siblings and mothers were observed given a proband with lymphoid leukemia, acute myeloid

leukemia, astrocytoma, certain gliomas, certain specified intracranial and intraspinal neoplasms,

nephroblastoma and other nonepithelial renal tumors, rhabdomyosarcomas, certain specified

soft tissue sarcomas, malignant gonadal germ cell tumors and certain unspecified carcinomas

(**Supplementary Table 4**).

When stratified by race/ethnicity, the relative risk of any cancer for siblings and mothers given a

proband with cancer was significantly higher among Latino subjects than non-Latino White

(NLW) subjects [Latino: SIR=3.36;95%CI:2.24-5.05; NLW: SIR=2.60;95%CI:1.66-4.06;

P=0.001]. Non-Latino Asians/Pacific Islanders (API) and Blacks also had higher SIRs than non-

Latino Whites (SIR=4.58 and 9.96, respectively, Supplementary Table 2), but small numbers

resulted in unstable estimates. Latino subjects also exhibited higher relative risks of any cancer

than NLW subjects for solid cancers [Latino: SIR=4.98;95%CI:2.86-8.68; NLW:

SIR=3.02;95%CI:1.72-5.28; *P*=0.001], while NLW subjects exhibited higher relative risks than

Latino subjects for hematologic cancers [Latino: SIR=2.48;95%CI:1.37-4.50; NLW:

SIR=2.69;95%CI:1.29-5.62; *P*=0.016] (**Figure 1B & Supplementary Table 2**). For the relative

risk of specific cancers given a proband with the same cancer, Latino subjects showed higher

relative risk of solid cancers than NLW subjects [Latino: SIR=7.94;95%CI:3.64-17.34; NLW:

SIR=4.41;95%CI:2.10-9.23; *P*=0.005] (**Supplementary Table 3**).

In the subgroup analysis of pediatric patients aged 0-15 years, we observed a similar trend

where the relative risk of any cancer for siblings and mothers was significantly higher among

Latino subjects than NLW subjects [Latino: SIR=1.51;95%CI:1.00-2.26; NLW:

SIR=0.93;95%CI:0.60-1.46; *P*=0.003] (**Supplementary Table 5**).

Relative risks of second primary malignancies

Overall, we found a 7.12-fold increased risk of SPMs relative to the general population among

children/AYAs with an FPM (SIR=7.12;95%CI:5.46-9.28). Most primary cancer types were

associated with an elevated relative risk of SPMs (**Figure 3A**). When stratified by race/ethnicity,

slightly higher relative risk of all SPMs given a proband with cancer was observed among Latino

subjects than NLW subjects [Latino: SIR=6.85;95%CI:4.56-10.30; NLW: SIR=6.67;95%CI:4.26-

10.43; *P*=0.001] (**Figure 3B**).

For the relative risks of SPMs of the same cancer types as the FPM, we found elevated risks for

both hematologic and solid cancers. When stratified by race/ethnicity, higher relative risk of

hematologic cancers was observed among NLW subjects compared to Latino subjects given a

proband with hematologic cancers [Latino: SIR=4.23;95%CI:1.68-10.68; NLW:

SIR=6.61;95%CI:1.80-24.29; *P*=0.012] (**Supplementary Table 6**).

Discussion

To our knowledge, this is the first study to quantify the familial clustering risks and risks of SPMs among early-onset cancer patients with an emphasis on racial/ethnic differences. Using linked population registry data in the California population, we found that the risk for a sibling child/AYA or mother to have early-onset cancer was elevated once a proband was identified with an early-onset cancer. Likewise, the relative risks for SPMs were elevated among children/AYAs who contracted a first primary cancer. The findings were consistent across race/ethnic groups; however, the magnitude was different. Latinos had higher sibling/maternal relative risks as well as risks for SPMs compared to NLWs for most cancers.

Consistent with our results, a rich literature with a primary focus on European ancestry populations has reported excessive familial risks of hematologic malignancies[14], lymphomas[23-25], brain tumors[26,27], neuroblastomas[28], retinoblastomas[25,28], germ cell tumors[29], sarcomas[30] and melanomas[31]. In terms of secondary cancers, studies have reported excessive risks of second primary malignancies among of survivors of hereditary retinoblastoma[32], chronic myeloid leukemia[33], chronic lymphocytic leukemia[34], Hodgkin's lymphoma[35], non- Hodgkin's lymphoma[36], and neuroblastoma[37]. The excessive familial risks of certain cancers are highly likely to be associated with genetic predisposition. The archetypic examples are germline loss-of-function mutations in *RB1*, which are found in ~40% of retinoblastoma cases[28], and adrenal cortical cancer, with germline *TP53* mutations accounting for most familial cases[28]. Low penetrance common genetic variations, for instance in *CEBPE*, *IKZF1*, and *ARID5B* genes in ALL, are associated with cancer risk and may also contribute to familial concordance as combinations of low frequency alleles or "polygenic risk scores" have been shown to be as impactful as single strong predisposition mutations in adult cancers[38,39]; however, their contribution to cancer clustering among children and their families has not yet been studied.

Our data demonstrate a higher degree of familial-based clustering among Latinos compared to

non-Latino Whites. This familial concordance is likely due to both shared genetic and

environmental causes and is accompanied by a clearly higher incidence of some cancer types.

Latinos are an admixed population, comprising an ancestral mixture from Native American,

European, and African sources. California Latinos, particularly the youth population are largely

from Mexico, and harbor a higher risk of certain cancers particularly pediatric leukemias, the

most common cancer in children[40]; however this higher risk is partially accounted for by a higher

frequency of common risk alleles which do not address strong familial predisposition loci[4]. This

higher risk identified in relation to the family unit has not been studied, and our results here beg

for an analysis of comparative sources of genetic and environmental risk that contribute to the

higher risk and familial clustering of cancers in Latinos.

Therapy of the first primary cancer is a major factor in the induction of secondary independent

malignancies[41-43]. The purpose of radiation and chemo-therapies of cancer patients is to

improve survivorship. In the current analysis, better survivorship of hematologic cancers for non-

Latino Whites compared to Latinos may however contribute to the excessive risk of second

primary malignancies among White subjects[44], as some Latino subjects with hematologic

cancers may not have survived long enough to develop a secondary cancer. Nevertheless,

multiple primary cancer diagnoses are considered a key feature of hereditary cancer

predisposition syndromes[45]. As such secondary cancers are rare, genetics are still likely to play

a strong role[46], and our overall SPM results here emphasize a similar ethnic-specific patterning

as cancer clustering in first primary malignancies. Of note, our analysis was not designed to

distinguish relative risk contributions from therapy and genetic sources for secondary cancers.

For some tumor types the germline predisposition was readily noted in this cohort, for example

ten of the fourteen affected relatives who had a proband with retinoblastoma were diagnosed

with the same cancer, an unsurprising finding given that germline *RB1* mutations account for a

significant proportion of retinoblastoma are highly penetrant and those tumors tend to be

diagnosed young. We also observed increased relative risks for sarcomas given a proband with

leukemias, suggesting the presence of families with Li-Fraumeni syndrome, which is

characterized by a spectrum of childhood and adult-onset cancers including adrenocortical

carcinoma, breast cancer, CNS tumors, sarcomas, and leukemia[45].

Population-level selection pressures are thought to influence the relative frequencies of alleles.

For instance, genetic adaptations that shaped the Native American genome to cold and warm

environments[47], and immune response following colonization by Europeans[48]. Our result

suggests that some adaptive selection pressures, or simply genetic drift exacerbated by

bottlenecking of genetic diversity during the Native American population history may

differentially influence familial cancer clustering by age of cancer onset[49]. If replicated in other

study settings, this contrast between genetic risk child and adult onset cancers by ethnicity

should be studied further for a fuller understanding of familial risks.

Our analyses capitalized on the highly diverse population in California, allowing us to quantify

the relative risks across different ethnic groups. Moreover, the utilization of linked population-

based registries in California enabled us to minimize the selection and information biases

introduced by a case-control study design or other strategies that only sample portions of the

population. Furthermore, although Latinos usually have more people per household than

NLWs[50], detection bias of cancers among siblings and mothers is less likely, which is reflected

by the excessive relative risk of lymphomas among NLW compared to Latino subjects in the

current analysis in agreement with previous reports[51,52]. There are also some limitations of our

study. Despite the large number of total cancer cases, the number of affected siblings and

second primaries are very small for some cancer types, thus limiting the power to detect

significant relative risks. Also, we are unable to track cancer incidence for affected siblings,

maternal cancers, and SPMs that may have been diagnosed outside of California. In addition,

the follow-up time of 26 years is not enough for a comprehensive detection of SPMs in the

probands, nor for cancers arising in proband mothers at older ages. These insufficient follow-up

time and loss-to follow-up issues have limited our ability to quantify the relative risks among

mothers with cancer onset at older ages (>40 yrs). Lastly, the lack of records on fathers reduces

our ability to quantify the relative risks among other first-degree relatives and may reduce the

appreciation of the potential contribution of high-risk cancer predisposition syndromes which can

be inherited from either parent.

Accepting those limitations with the current dataset, our study has several important implications

that may open windows to future research. First, the genetic predispositions driving the

excessive childhood cancer risks among the Latino population, whether from higher frequencies

of known cancer predisposition syndromes or mutations in novel genes, or a higher burden of

common or rare genetic risk alleles, warrants further investigation. Second, the comparative

attributable fraction of familial risk based on environmental risk factors interacting with genetic

predispositions warrants further investigation. Lastly, descriptive studies on familial and

secondary cancer risks among race/ethnic groups other than Latinos and non-Latino Whites

may provide additional insights into cancer incidence variation by race/ethnicity.

(2939 words)

Funding

This work was supported by the V Foundation for funding this work (Grant FP067172). The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s), and no endorsement by the California Department of Public Health, the National Cancer Institute, or the Centers for Disease Control and Prevention or their contractors and subcontractors is intended or should be inferred.

Declaration of interests

None.

References

1. Saletta F, Dalla Pozza L, Byrne JA. Genetic causes of cancer predisposition in children and adolescents. *Transl Pediatr.* 2015;4(2):67-75.
2. Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute lymphoblastic leukemia. *Blood.* 2015;125(26):3988-3995.
3. Caswell-Jin JL, Gupta T, Hall E, et al. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. *Genet Med.* 2018;20(2):234-239.
4. Walsh KM, Chokkalingam AP, Hsu LI, et al. Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children. *Leukemia.* 2013;27(12):2416-2419.
5. Ricker C, Culver JO, Lowstuter K, et al. Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. *Cancer Genet.* 2016;209(4):130-137.
6. Rampersaud E, Ziegler DS, Iacobucci I, et al. Germline deletion of ETV6 in familial acute lymphoblastic leukemia. *Blood Adv.* 2019;3(7):1039-1046.
7. Feng Q, de Smith AJ, Vergara-Lluri M, et al. Trends in Acute Lymphoblastic Leukemia Incidence in the US from 2000-2016: an Increased Risk in Latinos Across All Age Groups. In. *Am J Epidemiol.* Vol In press2020.
8. Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. *Neuro Oncol.* 2019;21(11):1357-1375.
9. Brown AL, Arroyo VM, Agrusa JE, Scheurer ME, Gramatges MM, Lupo PJ. Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment. *Cancer.* 2019;125(20):3623-3630.
10. Calip GS, Law EH, Ko NY. Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. *Breast Cancer Res Treat.* 2015;151(3):687-696.
11. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. *N Engl J Med.* 2015;373(24):2336-2346.
12. Plon SE, Lupo PJ. Genetic Predisposition to Childhood Cancer in the Genomic Era. *Annu Rev Genomics Hum Genet.* 2019;20:241-263.
13. Ripperger T, Bielack SS, Borkhardt A, et al. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. *Am J Med Genet A.* 2017;173(4):1017-1037.
14. Sud A, Chattopadhyay S, Thomsen H, et al. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. *Blood.* 2019;134(12):960-969.
15. Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. *BMJ.* 2012;345:e8076.
16. Hemminki K, Czene K. Attributable risks of familial cancer from the Family-Cancer Database. *Cancer Epidemiol Biomarkers Prev.* 2002;11(12):1638-1644.
17. Heath JA, Smibert E, Algar EM, Dite GS, Hopper JL. Cancer risks for relatives of children with cancer. *J Cancer Epidemiol.* 2014;2014:806076.
18. Curtin K, Smith KR, Fraser A, Pimentel R, Kohlmann W, Schiffman JD. Familial risk of childhood cancer and tumors in the Li-Fraumeni spectrum in the Utah Population Database: implications for genetic evaluation in pediatric practice. *Int J Cancer.* 2013;133(10):2444-2453.
19. Kohli DR, Smith KR, Wong J, et al. Familial pancreatic cancer risk: a population-based study in Utah. *J Gastroenterol.* 2019;54(12):1106-1112.

20. Samadder NJ, Curtin K, Wong J, et al. Epidemiology and familial risk of synchronous
and metachronous colorectal cancer: a population-based study in Utah. *Clin*
Gastroenterol Hepatol. 2014;12(12):2078-2084 e2071-2072.
21. Wang X, Harmon J, Zabrieskie N, et al. Using the Utah Population Database to assess
familial risk of primary open angle glaucoma. *Vision Res.* 2010;50(23):2391-2395.
22. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-
based assessment of cancer risk in first-degree relatives of cancer probands. *J Natl*
Cancer Inst. 1994;86(21):1600-1608.
23. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma.
Blood. 2015;126(20):2265-2273.
24. Fallah M, Kharazmi E, Pukkala E, et al. Familial risk of non-Hodgkin lymphoma by sex,
relationship, age at diagnosis and histology: a joint study from five Nordic countries.
Leukemia. 2016;30(2):373-378.
25. Madanat-Harjuoja LM, Pitkaniemi J, Hirvonen E, Malila N, Diller LR. Linking population-
based registries to identify familial cancer risk in childhood cancer. *Cancer.*
2020;126(13):3076-3083.
26. Couldwell WT, Cannon-Albright LA. A description of familial clustering of meningiomas in
the Utah population. *Neuro Oncol.* 2017;19(12):1683-1687.
27. Crump C, Sundquist J, Sieh W, Winkleby MA, Sundquist K. Perinatal and familial risk
factors for brain tumors in childhood through young adulthood. *Cancer Res.*
2015;75(3):576-583.
28. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and Neuroblastoma
Predisposition and Surveillance. *Clin Cancer Res.* 2017;23(13):e98-e106.
29. Landero-Huerta DA, Vigueras-Villasenor RM, Yokoyama-Rebollar E, et al. Epigenetic
and risk factors of testicular germ cell tumors: a brief review. *Front Biosci (Landmark*
Ed). 2017;22:1073-1098.
30. Lynch HT, Deters CA, Hogg D, Lynch JF, Kinarsky Y, Gatalica Z. Familial sarcoma:
challenging pedigrees. *Cancer.* 2003;98(9):1947-1957.
31. Frank C, Sundquist J, Hemminki A, Hemminki K. Risk of other Cancers in Families with
Melanoma: Novel Familial Links. *Sci Rep.* 2017;7:42601.
32. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of
second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. *J*
Natl Cancer Inst. 2008;100(24):1771-1779.
33. Sasaki K, Kantarjian HM, O'Brien S, et al. Incidence of second malignancies in patients
with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *Int J Hematol.*
2019;109(5):545-552.
34. Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and
pathogenesis with emphasis on the role of different therapies. *Leuk Lymphoma.*
2005;46(1):49-54.
35. Baker H. Second cancer risk for Hodgkin's lymphoma survivors. *Lancet Oncol.*
2016;17(2):e50.
36. Chattopadhyay S, Sud A, Zheng G, et al. Second primary cancers in non-Hodgkin
lymphoma: Bidirectional analyses suggesting role for immune dysfunction. *Int J Cancer.*
2018;143(10):2449-2457.
37. Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL. Second
malignancies in patients with neuroblastoma: the effects of risk-based therapy. *Pediatr*
Blood Cancer. 2015;62(1):128-133.
38. Fantus RJ, Helfand BT. Germline Genetics of Prostate Cancer: Time to Incorporate
Genetics into Early Detection Tools. *Clin Chem.* 2019;65(1):74-79.
39. Yadav S, Couch FJ. Germline Genetic Testing for Breast Cancer Risk: The Past,
Present, and Future. *Am Soc Clin Oncol Educ Book.* 2019;39:61-74.

40. Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-
Cowdin R. Trends in childhood leukemia incidence over two decades from 1992 to 2013.
Int J Cancer. 2017;140(5):1000-1008.
41. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when
genetics and environment collide. *Nat Rev Cancer.* 2017;17(9):513-527.
42. Mazonakis M, Kachris S, Damilakis J. Second Cancer Risk from Radiation Therapy for
Common Solid Tumors Diagnosed in Reproductive-Aged Females. *Radiat Prot
Dosimetry.* 2018;182(2):208-214.
43. Turcotte LM, Liu Q, Yasui Y, et al. Chemotherapy and Risk of Subsequent Malignant
Neoplasms in the Childhood Cancer Survivor Study Cohort. *J Clin Oncol.*
2019;37(34):3310-3319.
44. Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. *Blood.*
2017;130(15):1699-1705.
45. Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the
understanding of hereditary cancer predisposition. *Br J Haematol.* 2017;176(4):539-552.
46. Churpek JE, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility
genes are common among survivors of breast cancer who develop therapy-related
leukemia. *Cancer.* 2016;122(2):304-311.
47. Reynolds AW, Mata-Miguez J, Miro-Herrans A, et al. Comparing signals of natural
selection between three Indigenous North American populations. *Proc Natl Acad Sci U S
A.* 2019;116(19):9312-9317.
48. Lindo J, Huerta-Sanchez E, Nakagome S, et al. A time transect of exomes from a Native
American population before and after European contact. *Nat Commun.* 2016;7:13175.
49. O'Fallon BD, Fehren-Schmitz L. Native Americans experienced a strong population
bottleneck coincident with European contact. *Proc Natl Acad Sci U S A.*
2011;108(51):20444-20448.
50. bureau USC. Historical Households Tables. https://www.census.gov/data/tables/time-
series/demo/families/households.html. Published 2019. Accessed.
51. Center PR. Latinos in California, Texas, New York, Florida and New Jersey.
https://www.pewresearch.org/hispanic/2004/03/19/latinos-in-california-texas-new-york-
florida-and-new-jersey/. Published 2004. Accessed.
52. Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma
Incidence and Survival in the United States. *J Clin Oncol.* 2016;34(9):963-971.
479
480

Tables

Table 1. Abbreviations of the twelve broad groups defined by the International Classification of Childhood Cancer, Third edition.

Abbreviation	Definition [†]
Leukemias	I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases
Lymphomas	II. Lymphomas and reticuloendothelial neoplasms
CNS tumors	III. CNS and miscellaneous intracranial and intraspinal neoplasms
Neuroblastomas	IV. Neuroblastoma and other peripheral nervous cell tumors
Retinoblastoma	V. Retinoblastoma
Renal tumors	VI. Renal tumors
Hepatic tumors	VII. Hepatic tumors
Bone tumors	VIII. Malignant bone tumors
Sarcomas	IX. Soft tissue and other extraosseous sarcomas
GCT	X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads
Epithelial neoplasms	XI. Other malignant epithelial neoplasms and malignant melanomas
Other	XII. Other and unspecified malignant neoplasms

[†] Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html).

489 Table 2. Selected demographic characteristic of probands, affected siblings and second primary
490 malignancies among the early-onset cancer patients in the linked population-based registries in
491 California, 1989 to 2015.
492

	No. (%)				
	Overall *	No. of probands	No. of affected siblings	No. of affected mothers	No. of second primaries [†]
Overall	29 249	29 072	112	65	387
Age at diagnosis (years) [‡]					
0	2592 (8.75)	2611 (8.98)	10 (8.93)	0 (0.00)	4 (1.03)
1-4	8683 (29.3)	8719 (29.99)	15 (13.39)	2 (3.08)	37 (9.56)
5-9	5054 (17.06)	5057 (17.39)	12 (10.71)	0 (0.00)	67 (17.31)
10-14	4224 (14.26)	4180 (14.38)	22 (19.64)	0 (0.00)	98 (25.32)
15-19	4734 (15.98)	4664 (16.04)	37 (33.04)	7 (10.77)	90 (23.26)
20+	4344 (14.66)	3841 (13.21)	16 (14.29)	56 (86.15)	91 (23.51)
Gender					
Male	15 528 (52.40)	15 467 (53.20)	56 (50.00)	NA	198 (51.16)
Female	14 102 (47.59)	13 605 (46.80)	56 (50.00)	65 (100.00)	189 (48.84)
Race/ethnicity					
Latino (all races)	13 281 (44.82)	13 059 (44.92)	51 (45.54)	26 (40.00)	159 (41.09)
Non-Latino White	11 410 (38.51)	11 193 (38.50)	39 (34.82)	17 (26.15)	128 (33.07)
Non-Latino Black	1772 (5.98)	1716 (5.90)	9 (8.04)	7 (10.77)	10 (2.58)
Non-Latino Asian/Pacific Islander	2605 (8.79)	2551 (8.77)	12 (10.71)	0 (0.00)	47 (12.14)
Other	563 (1.94)	553 (1.90)	1 (0.89)	15 (4.62)	43 (11.11)

493 * All early-onset cancer patients diagnosed from 1989 to 2015 identified in the linked population-
494 based registries in California.
495 [†] Number of second primary malignancies diagnosed from 1989 to 2015 within all children
496 (probands and affected siblings, excluding mothers) with early-onset cancers in the linked
497 population-based registries in California.
498
499

Figures

Figure legend:

Figure 1: Relative risks of early-onset cancers among siblings and mothers.
A. Relative risks among siblings and mothers of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.
B. Relative risks by ethnic group among siblings and mothers of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.

Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html).
Hematologic cancers include leukemias and lymphomas. Solid cancers include CNS tumors, neuroblastomas, retinoblastomas, renal tumors, hepatic tumors, bone tumors, sarcomas, GCT, epithelial neoplasms and others.

The axis for SIR was natural log-transformed. SIR and 95% CI were not calculatable for cancers with zero observed case.
P was calculated assuming a Poisson distribution.
Abbreviations: SIR, Standardized incidence ratio. CI, confidence interval. GCT, germ cell tumors, trophoblastic tumors, and neoplasms of gonads.

Figure 2: Relative risks of siblings and mothers of specific cancers.
Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html).
Standardized incidence ratios greater than 10 were recoded to 10.
Siblings and mothers of a proband were diagnosed with cancer from 1989 to 2015 at 0 to 26 years of age.
P was calculated assuming a Poisson distribution.
Abbreviations: SIR, Standardized incidence ratio. CI, confidence interval. GCT, germ cell tumors, trophoblastic tumors, and neoplasms of gonads.

Figure 3. Relative risks of second primary malignancies.
A. Relative risks of second primary malignancies of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.
B. Relative risks of second primary malignancies of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer by ethnic group, 1989 to 2015, California, USA.

Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html).
Hematologic cancers include leukemias and lymphomas. Solid cancers include CNS tumors, neuroblastomas, retinoblastomas, renal tumors, hepatic tumors, bone tumors, sarcomas, GCT, epithelial neoplasms and others.

The axis for SIR was natural log-transformed. SIR and 95% CI were not calculatable for cancers with zero observed case.
P was calculated assuming a Poisson distribution.
Abbreviations: SIR, Standardized incidence ratio. CI, confidence interval. GCT, germ cell tumors, trophoblastic tumors, and neoplasms of gonads. FPM, first primary malignancy. SPM, second primary malignancy.

553   Figure 1A.

Group	No. of probands	No. of affected siblings and mothers		SIR of any cancer (95% CI)	P
Overall	29072	177		3.32 (2.54, 4.35)	<0.001
Hematologic cancers	11404	66		2.97 (1.96, 4.50)	<0.001
Solid cancers	17849	141		4.54 (3.19, 6.45)	<0.001
Leukemias	8500	51		2.87 (1.80, 4.57)	<0.001
Lymphomas	2928	21		4.66 (1.85, 11.75)	0.065
CNS tumors	5739	38		3.50 (1.93, 6.34)	0.002
Neuroblastomas	1445	7		2.01 (0.70, 5.76)	0.119
Retinoblastomas	718	14		8.03 (1.82, 35.43)	0.355
Renal tumors	1069	9		3.62 (1.04, 12.57)	0.220
Hepatic tumors	414	2		2.20 (0.28, 17.16)	0.622
Bone tumors	249	2		5.59 (0.21, 148.04)	0.891
Sarcomas	2915	40		7.85 (3.30, 18.72)	0.050
GCT	2423	20		5.97 (2.05, 17.41)	0.128
Epithelial neoplasms	3050	36		12.51 (3.94, 39.71)	0.171
Other	255	4		9.18 (0.47, 179.03)	0.851

-2.5   -1   0   1   2.5   5.5

555   Figure 1B.

Group	Non-Latino White SIR of any cancer (95% CI)	P	Latino all races SIR of any cancer (95% CI)	P		P comparing SIRs
Overall	2.60 (1.66, 4.06)	<0.001	3.36 (2.24, 5.05)	<0.001		0.001
Hematologic cancers	2.69 (1.29, 5.62)	0.015	2.48 (1.37, 4.50)	0.002		0.016
Solid cancers	3.02 (1.72, 5.28)	0.001	4.98 (2.86, 8.68)	0.001		0.001
Leukemias	2.11 (0.89, 4.96)	0.050	2.35 (1.22, 4.53)	0.005		0.004
Lymphomas	4.32 (1.02, 18.25)	0.331	4.10 (1.01, 16.64)	0.308		0.88
CNS tumors	2.63 (1.05, 6.58)	0.062	2.86 (1.10, 7.43)	0.076		0.767
Neuroblastomas	0.70 (0.14, 3.64)	0.441	1.70 (0.28, 10.32)	0.517		0.455
Retinoblastomas	3.65 (0.26, 51.45)	0.792	12.32 (1.24, 121.98)	0.702		0.016
Renal tumors	2.64 (0.28, 25.14)	0.690	2.91 (0.42, 20.03)	0.572		0.463
Hepatic tumors			2.43 (0.11, 51.51)	0.863		0.311
Bone tumors			6.06 (0.05, 755.63)	0.977		0.306
Sarcomas	3.77 (0.89, 15.87)	0.329	9.06 (2.42, 33.86)	0.262		0.003
GCT	3.42 (0.56, 20.99)	0.522	6.20 (1.32, 29.04)	0.387		0.04
Epithelial neoplasms	8.60 (1.85, 39.96)	0.383	15.16 (2.11, 108.71)	0.589		0.032
Other	10.49 (0.12, 932.36)	0.968	5.86 (0.05, 673.74)	0.975		0.313

-3   -1 0 1 2.5   5   7.5

565   Figure 2.

Figure 3A.

Group	No. of FPMs	No. of SPMs	SIR of any cancer (95% CI)	P
Overall	30059	387	7.12 (5.46 to 9.28)	<0.001
Hematologic cancers	11553	146	6.57 (4.33, 9.95)	<0.001
Solid cancers	18893	241	7.75 (5.45, 11.02)	<0.001
Leukemias	8543	116	6.38 (4.03 to 10.10)	<0.001
Lymphomas	2960	30	6.42 (2.59 to 15.90)	0.050
CNS tumors	5877	64	5.76 (3.20 to 10.37)	0.002
Neuroblastomas	1450	24	6.76 (2.39 to 19.12)	0.113
Retinoblastomas	728	24	13.48 (3.10 to 58.59)	0.346
Renal tumors	1078	13	5.09 (1.49 to 17.35)	0.210
Hepatic tumors	417	5	5.38 (0.70 to 41.12)	0.614
Bone tumors	250	8	21.56 (0.86 to 538.54)	0.884
Sarcomas	3028	68	12.90 (5.49 to 30.29)	0.041
GCT	2468	13	3.73 (1.31 to 10.65)	0.117
Epithelial neoplasms	3479	21	6.94 (2.25 to 21.44)	0.157
Other	261	1	2.22 (0.12 to 41.05)	0.843

Figure 3B.

Group	Non-Latino White SIR of any cancer (95% CI)	P	Latino all races SIR of any cancer (95% CI)	P		P comparing SIRs
Overall	6.67 (4.26 to 10.43)	<0.001	6.85 (4.56 to 10.30)	<0.001		0.001
Hematologic cancers	5.80 (2.78, 12.12)	0.015	5.61 (3.10, 10.17)	0.002		<0.001
Solid cancers	7.09 (4.05, 12.41)	0.001	7.87 (4.52, 13.72)	0.001		0.263
Leukemias	5.18 (2.20 to 12.23)	0.043	5.60 (2.91 to 10.79)	0.005		<0.001
Lymphomas	7.58 (1.79 to 32.09)	0.332	5.64 (1.39 to 22.92)	0.309		0.357
CNS tumors	5.71 (2.28 to 14.30)	0.062	6.43 (2.47 to 16.75)	0.077		0.639
Neuroblastomas	9.17 (1.77 to 47.54)	0.441	3.40 (0.56 to 20.66)	0.518		<0.001
Retinoblastomas	9.14 (0.65 to 129.39)	0.793	10.96 (1.11 to 108.65)	0.703		<0.001
Renal tumors	9.27 (0.97 to 88.47)	0.691	2.91 (0.42 to 20.05)	0.573		<0.001
Hepatic tumors			9.71 (0.46 to 205.74)	0.863		
Bone tumors	16.95 (0.06 to 5094.92)	0.991	18.18 (0.15 to 2265.63)	0.977		0.454
Sarcomas	10.25 (2.43 to 43.27)	0.330	14.50 (3.88 to 54.24)	0.262		0.014
GCT	3.43 (0.56 to 21.10)	0.523	4.97 (1.06 to 23.29)	0.388		0.112
Epithelial neoplasms	6.78 (1.46 to 31.57)	0.384	8.10 (1.13 to 58.17)	0.590		0.043
Other			5.88 (0.05 to 682.43)	0.976		

■ Non-Latino White
● Latino all races